Advocates on Steps of Congress 2013
Please leave this field empty

Ohio

Cincinnati 

University of Cincinnati Medical Center  – CTD-ILD and Scleroderma Clinic
200 Albert Sabin Way, Cincinnati, OH 45220. Third floor.

Phone: (513) 475-8523

Scheduler - Lisa Davis

Physicians Affiliated with this Center:

Rheumatology
Dr. Surabhi A. Khanna
Pulmonary
Interstitial lung disease (ILD)

Dr. Nishant Gupta
Dr. Frank McCormack
Dr. Gaurav Khanna

Pulmonary Hypertension
Dr. Jean Elwing 

Gastroenterology
Dr. Vidhya Kunnathur 

Nephrology
Dr. Suresh Kamath 

Chest Radiologist
Dr. Sangita Kapur 

Chest Pathologist
Dr. Dani Zander
Dr. Kathryn Wikenheiser-Brokamp 

Basic research
Dr. Satish Madala

Research Coordinator
Rebecca Ingledue

Research Information:

Studies Status
Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD). Accepting patients
Pulmonary Arterial Hypertension Clinical Trials Multiple clinical trial and registry opportunities are available.

Please contact UC Pulmonary Hypertension Research Team to review opportunities.

UC Pulmonary Hypertension Research Coordinator:  Emilee Orr, RN, (513) 558-3077

UC Pulmonary Research Manager:  Tammy Roads, (513) 558-2148

 

Toledo

University of Toledo Scleroderma Program
The Ruppert Center at University of Toledo Health Center Campus
3120 Glendale Ave, 1st floor
Toledo, Ohio 43614
Phone: 419-383-4271
Fax: 419-383-6244

Appointments: 419-383-3627

Clinic Information: Adult, adolescent and pediatric patients with systemic and localized scleroderma are seen within one week of requested appointment. The center’s hours are between 9:00 a.m. and 5:00 p.m. Monday through Friday.

Professionals Affiliated with this Center:

  • Bashar Kahaleh, M.D. Rheumatology
  • Nezam Altorok M.D., Rheumatology
  • Vivek Nagaraja, M.D., Rheumatology
  • Samer Khoury, M.D., Pulmonary hypertension
  • Fadi Safi, M.D., Interstitial lung disease
  • Ali Nawras, M.D., Gastroenterology, motility disorder
  • Martin C. Skie, M.D, Orthopedics: Hand and Microsurgery
  • Deepak Maholtra, M.D., Ph.D., Nephrology
  • Yongqing Wang, Ph.D., Basic research
  • Shadia Nada, Ph.D., Basic research
  • Jennifer Gelmore, R.N., Research coordinator
  • Jennifer Krzyston, R.N., Staff nurse
  • Oralia Hensley, administrative assistant, Oralia.Hensley@utoledo.edu

The center was established in 1992; currently we follow an approximately 130 SSc patients who are evaluated on regular basis. The core physicians affiliated with the center cover all facets of care needed in scleroderma. Over the years the center was involved in most of the major national and international clinical trials in SSc. Currently, we are involved in the following studies:

Studies

Status

Randomized Open Label Phase II/III Multicenter of High Dose Immunosuppressive Therapy (SCOT)

Closed

Role of vasopressin in scleroderma pathogenesis

Active

A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects with Diffuse Cutaneous Systemic Sclerosis with Interstitial Lung Disease.

Closed

Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis.

Closed

A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis.

Closed

Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program.

Active

The Effects of Pomalidomide, CC-220 and CC-122 on Scleroderma Vascular and Fibrotic Disorders.

Active

Epigenetic modification of endothelial and fibroblast gene expression in scleroderma.

Active

Educational Activities

The center has been active in Scleroderma Foundation Ohio Chapter. We participate regularly in speaking engagements at patient support group’s meetings, co-organize annual walk for cure fundraiser and provide CME talks on topics related to scleroderma at the University of Toledo and the various hospitals in NW Ohio.  Moreover, members presented abstracts and posters related to scleroderma regularly at the ACR, Scleroderma research workshops and world scleroderma congress meetings.